Opportunities for improving managed care for individuals with dementia: Part 1--The issues

Area of Science:

• Gerontology
• Neurology
• Healthcare Management

Background:

• Alzheimer's disease and related dementias (ADRD) represent a significant cause of disability in the elderly population.
• The prevalence and associated costs of ADRD are increasing, posing challenges for healthcare systems.
• The introduction of novel, high-cost pharmaceuticals for dementia treatment is impacting pharmacy expenditures.

Purpose of the Study:

• To review the prevalence, costs, and current treatments for Alzheimer's disease and related dementias.
• To analyze the potential impact of new dementia drugs on overall medical costs and patient quality of life.
• To highlight the future implications of ADRD on managed care organizations due to the aging demographic.

Main Methods:

• Literature review of prevalence, costs, and treatments for Alzheimer's disease and related dementias.
• Analysis of the economic impact of new dementia medications on healthcare utilization and quality of life.
• Examination of the challenges faced by managed care organizations in addressing the needs of an aging population with dementia.

Main Results:

• New dementia drugs, while increasing pharmacy costs, may lead to reduced overall medical expenses.
• These innovative treatments have the potential to enhance the quality of life for both dementia patients and their caregivers.
• Rising costs, service utilization, and quality of life concerns related to dementia will significantly affect managed care organizations.

Conclusions:

• Managed care organizations must prepare for the growing impact of Alzheimer's disease and related dementias.
• Strategic disease management programs, similar to those for chronic conditions like diabetes, are needed.
• Effective management strategies can improve patient outcomes and mitigate the financial burden of dementia care.